See Supplemental Patient Information
- Long-term use of corticosteroids may cause glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation; prolonged use may also increase the hazard of secondary ocular infections
- Long-term use of topical corticosteroids may cause corneal and scleral thinning. Avoid use in the presence of thin corneal or scleral tissue as it may lead to perforation
- Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication
- Regularly monitor intraocular pressure if this product is used for 10 days or longer
- Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation
- Use of ocular steroids may prolong the course and may exacerbate the severity of many ocular viral infections
- Administer with extreme caution in patients with a history of herpes simplex; perform frequent slit lamp microscopy in such patients
- Recommended for topical ophthalmic use only; not indicated for injection. It should never be injected subconjunctivally, nor should be directly introduced into the anterior chamber of the eye
- Products containing neomycin sulfate may cause cutaneous sensitization
- If signs and symptoms fail to improve after two days of therapy, the patient should be re-evaluated with the aid of magnification, such as a slit lamp biomicroscopy and fluorescein staining, where appropriate
- Fungal invasion should be suspected in any persistent corneal ulceration; fungal cultures should be taken when appropriate
- Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi
Cautions: Use cautiously in
Supplemental Patient Information
- Advise patients to discontinue use of the medication and consult a physician, if inflammation or pain persists longer than 48 hours or becomes aggravated
- Instruct patients to avoid touching the tip of the dispensing container to the eye, eyelid, or any other surface in order to prevent contamination of the product
- Advise patients not to wear contact lenses if they have signs and symptoms of bacterial ocular infection
Pregnancy Category:C
Breastfeeding: Safety unknown. Topical dexamethasone has not been studied during breastfeeding. It is unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infant by passage into breastmilk. Ophthalmic neomycin is excreted in very low levels in breastmilk and presents negligible risk to the infant. Polymyxin B is poorly absorbed; hence, may have minimal excretion in breast milk. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 16 June 2011). Manufacturer advises caution.
US Trade Name(s)
US Availability
dexamethasone/neomycin/polymyxin B (generic)
- OPTH DROPS: [0.1%/3.5 mg/10000 U]/mL
- OINT: [0.1%/3.5 mg/10000 U]/g
Dexasporin (dexamethasone/neomycin/polymyxin B)
- OPTH DROPS: [0.1%/3.5 mg/10000 U]/mL
Maxitrol (dexamethasone/neomycin/polymyxin B)
- OPTH DROPS: [0.1%/3.5 mg/10000 U]/mL
- OINT: [0.1%/3.5 mg/10000 U]/g
Canadian Trade Name(s)
Canadian Availability
Ak Trol (dexamethasone/neomycin/polymyxin B)
- SUSP: [1 mg/3.5 mg/10000 U]/mL
Dioptrol (dexamethasone/neomycin/polymyxin B)
- OINT: [1 mg/3.5 mg/10000 U]/g
- SUSP: [1 mg/3.5 mg/10000 U]/mL
Maxitrol (dexamethasone/neomycin/polymyxin B)
- OINT: [1 mg/3.5 mg/6000 U]/g
- SUSP: [1 mg/3.5 mg/6000 U]/mL
UK Trade Name(s)
UK Availability
Maxitrol (dexamethasone/neomycin/polymyxin B)
- DROPS: [1 mg/3500 U/6000 U]/mL
- OINT: [1 mg/3500 U/6000 U]/g
Australian Trade Name(s)
Australian Availability
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Maxitrol 5-10000-0.1 SUSP [Bottle] (ALCON VISION)
5 = $83.51
15 = $239.91
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
